Patent applications published 6 April 2011
Selected patent applications from the weekly European Patents Bulletin
- VEGF165 delivered by fibrin sealant to reduce tissue necrosis
Baxter International; Baxter Healthcare 2303011*
- Novel compounds, pharmaceutical compsns containing same, methods of use for same, and methods for preparing same
Fasgen; The Johns Hopkins University 2303013*
- Novel crystalline form of 2-[4-(4-fluor-benzyl)-piperidin-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
Richter Gedeon Nyrt 2303014*
- Methods and compsns using selective delta opioid receptor-1 agonists, delta opioid receptor-2 antagonists, and/or mu opioid
The Regents of the University of California 2303016*
- Inhibitors of AKT activity
GlaxoSmithKline 2303017*
- Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
Xcovery Holding Company 2303018*
- (6S)-5-methyltetrahydrofloic acid for therapy of tissue injury
Iskandar, Bermans; Hogan, Kirk 2303019*
- Preparation of controlled release skeletal muscle relaxant dosage forms
Eurand 2303020*
- Compounds for the treatment of cancer
University of Tennessee Research Foundation; The Ohio State University Research Foundation 2303021*
- Synergistic herbicidal combination of clomazone and pethoxamid
Cheminova 2303022*
- Process for preparing a carbapenem antibiotic compsn
Ranbaxy Laboratories 2303225*
- Sustained delivery of exenatide and other polypeptides
Endo Pharmaceuticals Solutions 2303226*
- Controlled release corticosteroid compsns and methods for the treatment of otic disorders
Otonomy; The Regents of the University of California 2303227*
- Fosphenytoin compsn
Texcontor Etablissement 2303228*
- Concentrated oxaliplatin solution and its method of preparation
Debiopharm 2303229*
- Methods and compsns for enhanced delivery of macromolecules
ESBATech 2303230*
- Preparation containing glucosamine and/or chondroitin for prophylaxis and treatment of arthrosis and for supporting the immune system
Lenghoff, Gertrud 2303231*
- Micronisable form of salmeterol xinafoate
INKE 2303232*
- Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
Pharmathen 2303233*
- Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
Stallergenes 2303234*
- Stabilisation of amorphous drugs using sponge-like carrier matrices
Capsulation NanoScience 2303235*
- Synergistic induction of humoral and cellular immunity of combinatorial activation of toll-like receptors
Emory University 2303236*
- Preparation method of biodegradable micro-particles containing drugs
Board of Trustees of the University of Arkansas 2303237*
- Solid dosage formulations of telcagepant potassium
Merck Sharp & Dohme 2303238*
- Directly pressed aliskiren tablets
Ratiopharm 2303239*
- Pharmaceutical compsns comprising 5-chloro0N({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thio-phencarboxamid
Ratiopharm 2303240*
- Process for making gastroretentive dosage forms
Université de la Méditerranée 2303241*
- Pharmaceutical dosage form comprising polymeric carrier compsn
Abbott 2303242*
- Oral compsn containing an anti-plaque agent of the thienopyridine family in the form of a base
CLL Pharma 2303243*
- Gastro-resistant pharmaceutical oral compsns comprising duloxetine or its pharmaceutically acceptable derivatives
KRKA 2303244*
- Degradable microcapsules
ETH Zurich; Swissgenetics 2303245*
- Polymersomes, colloidosomes, liposomes and other species associated with fluidic droplets
President and Fellows of Harvard College 2303246*
- Transdermal system for extended delivery of incretins and incretin mimetic peptides
Transpharma Medical 2303247*
- Dual spray can topical delivery device
McNeil-PPC 2303248*
- Anthraquinones and analogues from rheum palmatum for treatment of oestrogen receptor beta-mediated conditions
Bionovo 2303249*
- Paediatric compsns for treating multiple sclerosis
Novartis 2303250*
- New combination for use in the treatment of inflammatory disorders
Cardoz 2303251*
- Compounds for the treatment of metabolic syndrome and insulin resistance
Jungbauer, Alois 2303252*
- Methods and compsns for improving cognitive function
The Johns Hopkins University 2303253*
- Method fro treating chronic wounds with an extracellular polymeric substance solvating system
Medtronic Xomed 2303254*
- Pharmaceutical compsns useful for treatment of cancers, in particular acute myeloid leukaemia and acute promyelocytic leukaemia
Université Paris Diderot 2303255*
- Compounds useful for the prevention or treatment of accommodative asthenopia
Sigma-Tau Industrie Farmaceutiche Riunite 2303256*
- Rosmarinic acid from Origanum vulgare for treatment of diabetes
ACEF 2303257*
- Inhibitors of AKT activity
GlaxoSmithKline 2303258*
- Dronedarone for the prevention of cardioversion
Sanofi-Aventis 2303259*
- Methods for determining sensitivity to aminoflavones
Tigris Pharmaceuticals 2303260*
- Use of cyclolignans for the treatment of a hyperactive immune system
Axelar 2303261*
- DPP-IV inhibitors for use in the treatment of NAFLD
Boehringer Ingelheim International 2303262*
- Use
Pentraxin Therapeutics 2303263*
- Methods of treating alpha adrenergic mediated conditions
Allergan 2303264*
- Stable topical formulation comprising voriconazole
Glenmark Pharmaceuticals 2303265*
- Pharmaceutical compsn comprising a 4-hydrpxy-2-oxo-2,3-dihydro-1m3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity
AstraZeneca 2303266*
- Polymorphic form of A [1,2,4] trizolo [4,3-A] pyridine derivative for treating inflammatory diseases
Pfizer 2303267*
- Pharmaceutical compsns based on kinin B2 receptor antagonists and corticosteroids, and their use
Istituto Luso Farmaco d’Italia 2303268*
- Inhibitors of AKT activity
Merck Sharp & Dohme; Banyu Pharmaceutical 2303269*
- Acylamino-substituted fused cyclopentane-carboxylic acid derivatives and their use as pharmaceuticals
Sanofi-Aventis 2303270*
- Treatment of antibiotic-resistant bacteria infection
Taigen Biotechnology 2303271*
- Sofinicline (ABT-894) for attention deficit/hyperactivity disorder
Abbott Laboratories 2303272*
- Medical intervention in haematological cancers
Medizinische Universität Innsbruck 2303273*
- Multiple myeloma treatments
Pharma Mar 2303274*
- Smoothened receptor modulators
Duke University 2303275*
- Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl) piperidin-4-yl]oxy}quinazoline
AstraZeneca 2303276*
- Compsn for modulating stem cell growth with prostaglandins
Sucampo 2303278*
- Topical steroidal formulations
Temple University of the Commonwealth System of Higher Education 2303279*
- Compsns and methods for treatment of inflammation and hyperkeratotic lesions
Novelix Pharmaceuticals 2303280*